Today's edition · Thursday, November 19, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechMaryland

Health & TechSilver Spring, Maryland

FDA approves the first drug for the neurological symptoms of Type 3 Gaucher disease

Infilbray, a daily pill that reaches the brain, improved a combined coordination and thinking score versus enzyme infusions in a 52-week trial of 43 patients. Survival was not the measure.

Verified · Source: U.S. FDANov 18, 2026 · 1 min read
How to help
A scientist in a gray sweater working with tubes and bottles at a laboratory bench
Illustrative photo of a laboratory researcher. This is not a patient in the Infilbray trial, and it is not the FDA. Diane A. Reid / Wikimedia Commons · Public domain

Read the original

The reporting lives at U.S. FDA. Our summary is checked against it, and we link it on every story.

The Food and Drug Administration on November 18, 2026, approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease in adults and in children who weigh at least 15 kilograms, about 33 pounds. The agency said the pill crosses the blood-brain barrier and works as a glucosylceramide synthase inhibitor, slowing the buildup of fatty substances the body cannot break down. Type 3 disease, unlike type 1, affects the brain and can worsen balance, speech, memory, and thinking. The approval went to Genzyme Corporation, a Sanofi company, after orphan-drug designation and priority review.

The evidence is a randomized, double-blind study of 43 patients age 12 and older who were already stable on enzyme replacement therapy. For 52 weeks they took Infilbray once a day or continued intravenous enzyme therapy every two weeks. At week 52, the Infilbray group did better on a score that combined a coordination measure and a thinking measure. The FDA did not report a survival difference. The most common side effects were gastrointestinal symptoms and effects on mood. Serious psychiatric risks, including suicidal thoughts and behavior, have been reported. Animal studies flagged possible clouding of vision in younger patients and harm to a fetus if the drug is taken during pregnancy. The label has the full risk list.

More good news

Other stories in the same neighborhood of kindness.

A row of glass laboratory beakers on a white surfaceHealth & Tech
Silver Spring, Maryland

The FDA approved a pre-surgery bladder cancer combo

The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.

Verified · U.S. Food and Drug Administration